Cargando…

Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database

OBJECTIVES: Adverse reactions to the COVID-19 vaccines have been of interest since their emergency authorization. Cutaneous manifestations of the vaccines are not well studied. We aimed to characterize cutaneous reactions to the Moderna (mRNA-1273) and the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: Falotico, Julianne M., Desai, Amar D., Shah, Asghar, Ricardo, Jose W., Lipner, Shari R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361907/
https://www.ncbi.nlm.nih.gov/pubmed/35931925
http://dx.doi.org/10.1007/s40257-022-00715-x
_version_ 1784764621924597760
author Falotico, Julianne M.
Desai, Amar D.
Shah, Asghar
Ricardo, Jose W.
Lipner, Shari R.
author_facet Falotico, Julianne M.
Desai, Amar D.
Shah, Asghar
Ricardo, Jose W.
Lipner, Shari R.
author_sort Falotico, Julianne M.
collection PubMed
description OBJECTIVES: Adverse reactions to the COVID-19 vaccines have been of interest since their emergency authorization. Cutaneous manifestations of the vaccines are not well studied. We aimed to characterize cutaneous reactions to the Moderna (mRNA-1273) and the Pfizer-BioNTech (BNT162b2) COVID-19 vaccines on a large, national scale. METHODS: The Vaccine Adverse Event Reporting System was filtered for cutaneous and hair and nail reactions to the COVID-19 vaccines. Patient demographics and past medical histories, vaccine manufacturer and dosing, symptom timing, reaction location, and patient outcomes were extracted from each report. RESULTS: As of December 24, 2021, there were 67,273 cutaneous reactions to all COVID-19 vaccines, with most patients receiving the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines. The most common reactions overall were injection-site reaction, urticaria, and papular rash, with injection-site reaction more common after the Moderna (mRNA-1273) vaccine, and all other cutaneous reactions more common after the Pfizer-BioNTech (BNT162b2) vaccine. Patients with past histories of psoriasis, urticaria, and local site reactions to a vaccine were more likely to report these same symptoms after the COVID-19 vaccine. CONCLUSION: Patients should be counseled about these potential dermatologic reactions to the COVID-19 vaccines. Most occur within the first few days after vaccination, and are mild and self-limiting. Patients should therefore be encouraged that it is safe to receive the COVID-19 vaccine from a dermatological perspective.
format Online
Article
Text
id pubmed-9361907
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-93619072022-08-10 Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database Falotico, Julianne M. Desai, Amar D. Shah, Asghar Ricardo, Jose W. Lipner, Shari R. Am J Clin Dermatol Original Research Article OBJECTIVES: Adverse reactions to the COVID-19 vaccines have been of interest since their emergency authorization. Cutaneous manifestations of the vaccines are not well studied. We aimed to characterize cutaneous reactions to the Moderna (mRNA-1273) and the Pfizer-BioNTech (BNT162b2) COVID-19 vaccines on a large, national scale. METHODS: The Vaccine Adverse Event Reporting System was filtered for cutaneous and hair and nail reactions to the COVID-19 vaccines. Patient demographics and past medical histories, vaccine manufacturer and dosing, symptom timing, reaction location, and patient outcomes were extracted from each report. RESULTS: As of December 24, 2021, there were 67,273 cutaneous reactions to all COVID-19 vaccines, with most patients receiving the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines. The most common reactions overall were injection-site reaction, urticaria, and papular rash, with injection-site reaction more common after the Moderna (mRNA-1273) vaccine, and all other cutaneous reactions more common after the Pfizer-BioNTech (BNT162b2) vaccine. Patients with past histories of psoriasis, urticaria, and local site reactions to a vaccine were more likely to report these same symptoms after the COVID-19 vaccine. CONCLUSION: Patients should be counseled about these potential dermatologic reactions to the COVID-19 vaccines. Most occur within the first few days after vaccination, and are mild and self-limiting. Patients should therefore be encouraged that it is safe to receive the COVID-19 vaccine from a dermatological perspective. Springer International Publishing 2022-08-05 2022 /pmc/articles/PMC9361907/ /pubmed/35931925 http://dx.doi.org/10.1007/s40257-022-00715-x Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Research Article
Falotico, Julianne M.
Desai, Amar D.
Shah, Asghar
Ricardo, Jose W.
Lipner, Shari R.
Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database
title Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database
title_full Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database
title_fullStr Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database
title_full_unstemmed Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database
title_short Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database
title_sort curbing covid-19 vaccine hesitancy from a dermatological standpoint: analysis of cutaneous reactions in the vaccine adverse event reporting system (vaers) database
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361907/
https://www.ncbi.nlm.nih.gov/pubmed/35931925
http://dx.doi.org/10.1007/s40257-022-00715-x
work_keys_str_mv AT faloticojuliannem curbingcovid19vaccinehesitancyfromadermatologicalstandpointanalysisofcutaneousreactionsinthevaccineadverseeventreportingsystemvaersdatabase
AT desaiamard curbingcovid19vaccinehesitancyfromadermatologicalstandpointanalysisofcutaneousreactionsinthevaccineadverseeventreportingsystemvaersdatabase
AT shahasghar curbingcovid19vaccinehesitancyfromadermatologicalstandpointanalysisofcutaneousreactionsinthevaccineadverseeventreportingsystemvaersdatabase
AT ricardojosew curbingcovid19vaccinehesitancyfromadermatologicalstandpointanalysisofcutaneousreactionsinthevaccineadverseeventreportingsystemvaersdatabase
AT lipnersharir curbingcovid19vaccinehesitancyfromadermatologicalstandpointanalysisofcutaneousreactionsinthevaccineadverseeventreportingsystemvaersdatabase